The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
Novo Nordisk’s stock tumbles as drugmaker lays out case for declining sales in 2026
Related Posts
Add A Comment
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.